Skip to main content
Journal of Clinical Neurology (Seoul, Korea) logoLink to Journal of Clinical Neurology (Seoul, Korea)
. 2023 Feb 20;19(2):214. doi: 10.3988/jcn.2022.18.5.547e

Erratum: Effects of Cannabidiol on Adaptive Behavior and Quality of Life in Pediatric Patients With Treatment-Resistant Epilepsy

Se Hee Kim a, Han Som Choi b, Chung Mo Koo c, Bong-Rim Joo d, Byung-Joo Park e,f, Hae Kook Lee f,g, Joon Soo Lee a, Heung Dong Kim a, Hoon-Chul Kang a,f
PMCID: PMC9982176  PMID: 36854341

J Clin Neurol 2022;18(5):547-552 / https://doi.org/10.3988/jcn.2022.18.5.547

We would like to revise the contents of the methods as below.

CBD was prescribed on the first visit when screening was performed. An oral pharmaceutical formulation of highly purified CBD (100 mg/mL; Epidiolex, GW Research, Cambridge, United Kingdom) was used. The starting dosage of CBD ranged between 2.5-5 mg/kg/day, which was titrated to 10 mg/kg/day after 2 weeks. If a patient continued to have seizures, the dose could be increased up to 20 mg/kg/day.

graphic file with name jcn-19-214-g001.jpg

Fig. 1. Study design. A 2-week of titration was followed by 22 weeks of maintenance period. The starting dosage of cannabidiol ranged between 2.5-5 mg/kg/day, which was titrated to 10 mg/kg/day after 2 weeks. The dose could be increased up to 20 mg/kg/day. CBD, cannabidiol; QOLCE: Quality of Life in Childhood Epilepsy


Articles from Journal of Clinical Neurology (Seoul, Korea) are provided here courtesy of Korean Neurological Association

RESOURCES